Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · IEX Real-Time Price · USD
5.65
+0.72 (14.60%)
At close: Mar 28, 2024, 4:00 PM
5.55
-0.10 (-1.77%)
After-hours: Mar 28, 2024, 7:59 PM EDT
Sutro Biopharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Sutro Biopharma stock have an average target of 14.29, with a low estimate of 8.00 and a high estimate of 25. The average target predicts an increase of 152.92% from the current stock price of 5.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for STRO stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Oppenheimer | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +76.99% | Mar 28, 2024 |
Oppenheimer | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +76.99% | Mar 27, 2024 |
Wedbush | Wedbush | Buy Maintains $12 → $8 | Buy | Maintains | $12 → $8 | +41.59% | Mar 26, 2024 |
JMP Securities | JMP Securities | Buy Reiterates $17 | Buy | Reiterates | $17 | +200.88% | Mar 26, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +183.19% | Mar 26, 2024 |
Financial Forecast
Revenue This Year
52.85M
from 67.77M
Decreased by -22.02%
Revenue Next Year
48.95M
from 52.85M
Decreased by -7.38%
EPS This Year
-3.20
from -2.35
EPS Next Year
-3.51
from -3.20
Revenue Forecast
Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | 60.9M | 76.5M | 110.1M | 297.2M | 697.2M | 930.3M |
Avg | 52.8M | 48.9M | 66.1M | 115.6M | 293.5M | 502.4M |
Low | 44.1M | 23.5M | 39.2M | 10.3M | 56.4M | 229.2M |
Revenue Growth
Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | -10.1% | 44.8% | 124.8% | 349.9% | 503.3% | 217.0% |
Avg | -22.0% | -7.4% | 34.9% | 75.0% | 154.0% | 71.2% |
Low | -34.9% | -55.5% | -19.9% | -84.4% | -51.2% | -21.9% |
EPS Forecast
EPS | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | -3.18 | -2.70 | -1.63 | -0.77 | 2.72 | 4.21 |
Avg | -3.20 | -3.51 | -3.34 | -1.97 | -0.38 | 0.97 |
Low | -3.15 | -3.91 | -4.70 | -3.36 | -2.60 | -2.07 |
EPS Growth
EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | - | - | - | - | - | - |
Avg | - | - | - | - | - | - |
Low | - | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.